Loading...

PRLD PRELUDE THERAPEUTICS INC Management Changes 8-K Filing

PRLD

PRLD

PRELUDE THERAPEUTICS INC

(PRLD)

2025 8-K

Financial Results Announced

Exclusive Option Agreement

Compliance Regained

Financial Results Update

Financial Statements

Product Expansion

Financial Results

CFO Appointment

Strategic Partnership

Financial Results

Clinical Data Update

Clinical Data Release

ESMO Announcement

Financial Results

Annual Meeting of Stockholders

Presentation and Educationa...

Appointment and Stock Optio...

Financial Results Announcement

Departure of Chief Financia...

Financial Results Announcement

Securities Purchase Agreement

Financial Results Announcement

Earnings Reports

Annual Meeting Results

Investor Conferences

Entry into a Material Defin...

Financial Results and Inves...

Sales Agreement with Jeffer...

Financial Results and Colla...

Investor Presentation

Amended and Restated Bylaws

Investor Presentation

External Links:

On June 11, 2025, Prelude Therapeutics announced the appointment of Dr. Paul Scherer to its Board of Directors, effective following the Annual Meeting on June 12, 2025. He will also receive stock options for 76,000 shares and serve until the 2026 meeting.

AI Assistant

PRELUDE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.